IL13RA2 and neoplasm: Therefore, to validate Pep-1L as an in vivo IL13RA2 targeting platform, we utilized PET/CT molecular imaging to visualize real-time Cu-64 labeled Pep-1L binding to a standard IL13RA2-expressing tumor.